Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies.
about
Major depressive disorder in older adults: benefits and hazards of prolonged treatmentDepression, antidepressants, and bone health in older adults: a systematic reviewDo premenopausal women with major depression have low bone mineral density? A 36-month prospective studySerotonin transporter deficiency drives estrogen-dependent obesity and glucose intoleranceRisk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case-Control Study in Australia.Screening, assessment, and treatment of osteoporosis for the nurse practitioner: key questions and answers for clinical practice--a Canadian perspectiveEffects of escitalopram on markers of bone turnover: a randomized clinical trialDoes medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational dataMedication-induced osteoporosis: screening and treatment strategiesEffects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression.Do Selective Serotonin Reuptake Inhibitors (SSRIs) Cause Fractures?The colon: from banal to brilliant.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Zolpidem use and risk of fractures: a systematic review and meta-analysis.SSRIs: bad to the bone?Brains, bones, and aging: psychotropic medications and bone health among older adults.Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and doseCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsThe incidence and risk of osteoporosis in patients with anxiety disorder: A Population-based retrospective cohort study.Are selective serotonin reuptake inhibitors associated with fractures?Pharmacogenomics of osteoporosis: a pathway approach.The role of the gastrointestinal tract in calcium homeostasis and bone remodeling.Bone mineral density in adolescents with eating disorders exposed to selective serotonin reuptake inhibitors.Adverse skeletal effects of drugs - beyond Glucocorticoids.Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures.Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease.Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures.The association between use of antidepressants and bone quality using quantitative heel ultrasound.Serotonin: a novel bone mass controller may have implications for alveolar boneBone mineral density in a cohort of Estonian women with major depression.Emerging evidence on the link between depressive symptoms and bone loss in postmenopausal women.Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database.Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort.Risk of bipolar disorder and psychotic features in patients initially hospitalised with severe depression.Depressive symptoms are not associated with forearm bone accrual during adolescence.Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies.Medication use before and after hip fracture: a population-based cohort and case-control study.Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update.Antidepressant use and risk of adverse outcomes in people aged 20-64 years: cohort study using a primary care database.
P2860
Q27003857-574C6233-1D22-4DB5-8489-E5A603120C93Q27010527-456E97FF-DB8A-4CDF-8371-74401CC98A70Q28728705-FC33DB43-5987-4BE5-B54B-A304C357A8B0Q33682164-A5B3DA51-29C1-4139-B24D-C72099DB0F56Q33758585-97A05134-C9F3-4C58-8A32-6FF9A127D012Q34074981-0BA61534-9394-4922-88AC-D8CBC40C52F1Q34130880-78D9D633-F7A4-4A6C-A55E-D6BF4888BCE0Q34316224-F8C7F32A-CBE0-42E5-AF7B-B58F815A620EQ34389358-4A8DC017-3D6E-4CB3-B9A5-BDB53C7D2678Q34501008-7A6D9A93-9946-4C1B-81B7-8A5AE1808076Q34536565-CB8C8AB0-AC7D-462C-8738-7EAA65493C86Q35017883-0F8BFB08-EC30-4AA7-B9E5-E6C3A1DB08FFQ35754726-1B0657A5-5C93-41A0-8DFF-868AE029D503Q35997150-07A995E8-690B-44FB-A5B6-8D163FDDA0D6Q36235126-B42079AC-D503-4B4F-85D8-114DD28456AFQ36427958-4DC0BEA9-0A5A-440B-8C4F-8A7932502284Q36855935-0C8B765A-CBC1-4F45-9655-7A9A6ED2F59FQ37197216-011E31F0-531F-47E6-ACF5-342D4C3AE00AQ37300637-CC15FFAE-B368-4D6A-95C1-353410FD6CFFQ37384471-78DF241E-D5EC-4247-A352-0694328B95AEQ38010749-B6054DC4-32BF-40F5-9E67-FF4946E238EEQ38093799-E352B1D4-9F1F-449E-96FF-5DF760CF41D0Q38100210-B62BF8BA-ECC5-42B1-AF19-297A2283344DQ38231316-D2F05566-EAF5-4AD3-B2AF-09C98F17E797Q38830294-4044354E-808A-4344-BD80-B2B632FA8124Q39398828-972D912C-05A6-4654-8F69-A10F7AF28B1AQ39818593-8AC33013-EA67-488F-93E9-3DECF4F3F448Q39869513-981B134E-312A-4265-805D-00226FDB6005Q41585462-FCF575F6-50C7-49CE-84DD-E736B2E7C035Q42590314-CD705717-6A25-475F-9146-BA1E34F71CC4Q44454356-19687260-2F65-4E27-9491-900D5091D06CQ47653185-0F585516-D9F1-49F3-B95A-4FEE38DD8E35Q47736466-64B0712A-A15E-4478-B1E8-A056637CD900Q48051950-95B60594-3D43-4114-86CD-89EBCA0E0F31Q48148091-A102174B-D2D4-4298-AADB-BE8EF7AD74AAQ48336839-C9B3B71C-B1B7-42E5-BDEC-15D4819CB850Q48576448-51CCB022-F495-461C-BB16-C5FC4C759EDDQ51140318-FC2F8333-69A3-49EB-8A46-DE156061D082Q51761248-71BF0101-FF06-4853-8E33-C82E530179A2Q52668836-F2DB0658-6CD3-4E1E-A56E-2171D78F3D1D
P2860
Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Selective serotonin reuptake i ...... hort and case-control studies.
@ast
Selective serotonin reuptake i ...... hort and case-control studies.
@en
Selective serotonin reuptake i ...... hort and case-control studies.
@nl
type
label
Selective serotonin reuptake i ...... hort and case-control studies.
@ast
Selective serotonin reuptake i ...... hort and case-control studies.
@en
Selective serotonin reuptake i ...... hort and case-control studies.
@nl
prefLabel
Selective serotonin reuptake i ...... hort and case-control studies.
@ast
Selective serotonin reuptake i ...... hort and case-control studies.
@en
Selective serotonin reuptake i ...... hort and case-control studies.
@nl
P2093
P2860
P1476
Selective serotonin reuptake i ...... ohort and case-control studies
@en
P2093
P2860
P2888
P304
P356
10.1007/S00198-011-1778-8
P407
P577
2011-09-09T00:00:00Z